RadNet to absorb mammography AI developer iCad in $103M deal
The all-stock transaction is valued at about $103 million, or a 98% premium over iCad’s recent share price. The deal is slated to close in the third quarter of this year.
The all-stock transaction is valued at about $103 million, or a 98% premium over iCad’s recent share price. The deal is slated to close in the third quarter of this year.
